アクセス数 : ?
ダウンロード数 : ?
ID 115331
タイトル別表記
甲状腺未分化癌同所移植SCIDマウスモデルへのパクリタキセルとレンバチニブの有効性に対する小動物用FDG-PET/CTを用いた非侵襲的モニタリング
MONITORING ANAPLASTIC THYROID CANCER MODELS BY PET/CT
著者
青山, 万理子 徳島大学大学院医科学教育部(医学専攻) 徳島大学 教育研究者総覧 KAKEN研究者をさがす
キーワード
anaplastic thyroid carcinoma
orthotopic model
18F-FDG PET/CT
paclitaxel
lenvatinib
資料タイプ
学位論文
抄録
Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid carcinoma with a poor prognosis. Thus, suitable preclinical tumor models are required for the development of new ATC therapies. In the present study, orthotopic tumor xenograft models were established using ATC cell lines and SCID mice, and tumor invasion and the effects of anticancer drugs were evaluated using positron emission tomography/computed tomography (PET/CT) to repeatedly and non-invasively monitor these models. Three ATC cell lines (8305c, 8505c, and ACT-1) were used. Their sensitivities to two anticancer drugs (paclitaxel and lenvatinib) were investigated. The 8505c cell line was orthotopically implanted into SCID mice, which were then divided into three groups: no chemotherapy, paclitaxel (5 mg/kg, administered intraperitoneally, every week), and lenvatinib (5 mg/kg, oral route, every day) groups. PET/CT was performed and tumor growth and the effects of anticancer drugs based on tumor volume and fludeoxyglucose (FDG) uptake were evaluated. 8505c cells exhibited the highest sensitivity to the anticancer drugs. In mice implanted with 8505c cells, continuous increases in FDG uptake associated with tumor growth were detected on PET/CT in the group that received no chemotherapy. The tumor volume and FDG uptake increased by 91.5- and 2.4-fold, respectively, within 2 weeks. The increase observed in tumor volume was 26.9- and 12.2-fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. Furthermore, the increase in FDG uptake was 1.8-fold and 1.6-fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. In our orthotopic SCID mouse model, tumor growth and the effects of anticancer drugs were repeatedly and non-invasively monitored using PET/CT. The present method is useful for the development of new ATC treatments.
掲載誌名
Oncology Reports
ISSN
1021335X
17912431
cat書誌ID
AA11016405
出版者
Spandidos Publications
44
4
開始ページ
1709
終了ページ
1716
発行日
2020-08-07
備考
内容要旨・審査要旨・論文本文の公開
本論文は,著者Mariko Aoyamaの学位論文として提出され,学位審査・授与の対象となっている。
論文本文は2021-02-07以降公開予定。
出版社版DOI
出版社版URL
フルテキストファイル
言語
jpn
著者版フラグ
その他
文科省報告番号
甲第3461号
学位記番号
甲医第1468号
学位授与年月日
2020-09-24
学位名
博士(医学)
学位授与機関
徳島大学
部局
医学系
放射線総合センター
病院